13,307 Shares in Contineum Therapeutics, Inc. (NASDAQ:CTNM) Acquired by Nuveen Asset Management LLC

Nuveen Asset Management LLC purchased a new position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 13,307 shares of the company’s stock, valued at approximately $195,000. Nuveen Asset Management LLC owned 0.05% of Contineum Therapeutics at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of CTNM. Legal & General Group Plc increased its holdings in Contineum Therapeutics by 74.0% in the 4th quarter. Legal & General Group Plc now owns 3,631 shares of the company’s stock worth $53,000 after buying an additional 1,544 shares during the period. Corebridge Financial Inc. increased its holdings in Contineum Therapeutics by 73.1% in the 4th quarter. Corebridge Financial Inc. now owns 5,215 shares of the company’s stock worth $76,000 after buying an additional 2,202 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Contineum Therapeutics by 90.4% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,860 shares of the company’s stock worth $86,000 after buying an additional 2,783 shares during the period. MetLife Investment Management LLC acquired a new position in Contineum Therapeutics in the 4th quarter worth approximately $103,000. Finally, Rhumbline Advisers increased its holdings in Contineum Therapeutics by 36.3% in the 4th quarter. Rhumbline Advisers now owns 8,233 shares of the company’s stock worth $121,000 after buying an additional 2,191 shares during the period.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on CTNM shares. Robert W. Baird dropped their price objective on shares of Contineum Therapeutics from $32.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, March 7th. Morgan Stanley dropped their price objective on shares of Contineum Therapeutics from $25.00 to $20.00 and set an “overweight” rating on the stock in a research note on Monday, May 19th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $31.00 price objective on shares of Contineum Therapeutics in a research note on Thursday, May 15th. Finally, Jones Trading assumed coverage on shares of Contineum Therapeutics in a research note on Thursday, March 13th. They set a “buy” rating and a $23.00 price objective on the stock. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $22.50.

Contineum Therapeutics Stock Performance

Contineum Therapeutics stock opened at $4.75 on Friday. The company’s fifty day moving average price is $4.31 and its 200 day moving average price is $8.59. Contineum Therapeutics, Inc. has a 1 year low of $3.35 and a 1 year high of $22.00. The stock has a market capitalization of $122.89 million and a P/E ratio of -2.41.

Contineum Therapeutics (NASDAQ:CTNM) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06). Sell-side analysts predict that Contineum Therapeutics, Inc. will post -2.01 EPS for the current year.

Contineum Therapeutics Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).